I'm with you Brabus, why raise money from shareholders if buyers are lining up to buy Ropren?
We've been hearing this story for far too long. If everyone wants Ropren, why don't they sell it?
Shareholders suffered badly over the Opes Prime indiscretion, and as a shareholder I am not convinced, and have been given no evidence by management, that there is any demand for their product.
Sales figures are long overdue.
Cheers
SLA Price at posting:
24.2¢ Sentiment: Hold Disclosure: Held